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Background: A new propylene glycol-free and reduced-volume formulation of diclofenac 
sodium 75 mg/mL designed for intradeltoid administration has been found to be bioequivalent 
to a reference formulation of diclofenac sodium 75 mg/3 mL given via the intragluteal route 
in normal healthy volunteers. Standard needles may not reach the gluteus maximus muscle in 
many cases, especially in the obese. The objective of this study was to determine the pharma-
cokinetic parameters of the new formulation and compare the bioavailability of intradeltoid 
diclofenac sodium 75 mg/mL with that of the intragluteal 75 mg/3 mL reference formulation 
in obese volunteers.
Methods: A comparative, two-way, single-dose, bioavailability study was carried out in 10 
obese (body mass index . 25) male Indian volunteers after a washout period of seven days. 
Blood samples were collected until six hours following drug administration and analyzed using 
a prevalidated high-pressure liquid chromatography method.
Results: The mean maximum plasma concentration and time to reach maximum plasma con-
centration for the test formulation were 1.30 µg/mL and 0.50 hours, respectively, versus 0.93 µg/
mL and 1.08 hours for the reference formulation. The mean areas under the curve from 0 to 
last measurable time point (AUC0–t) for the test and reference formulations were 2.71 µg⋅h/mL 
and 2.73 µg⋅h/mL, respectively. The mean AUCs from 0 to infinity (AUC0–∞) for the test and 
reference formulations were 3.71 µg⋅h/mL and 3.75 µg⋅h/mL, respectively.
Conclusion: The results suggest that the test formulation of diclofenac sodium 75 mg/mL has 
an AUC0–t and AUC0–∞ comparable with the reference intragluteal formulation of diclofenac 
sodium 75 mg/3 mL, but with an earlier time to reach maximum plasma concentration and a 
trend towards a higher maximum plasma concentration. This could be attributed to faster absorp-
tion from the deltoid region than from the gluteal region. The test formulation could be helpful 
in the management of pain in obese or overweight patients and those with dense subcutaneous 
fat in the gluteal area.
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Introduction
Injectable nonsteroidal anti-inflammatory drugs are commonly used to reduce 
  postoperative pain. They are inexpensive and have been tested over time. They have 
also been reported to lessen postoperative narcotic requirements and narcotic side 
effects, including respiratory depression and nausea.1,2
Diclofenac sodium injection is effective and well tolerated in the management of 
postoperative pain1–3 and is currently marketed worldwide in a 3 mL injectable intra-
muscular formulation. It is generally administered intragluteally. However, the standard 
needles used may not reach the gluteus maximus muscle in patients who are obese.4–7Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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For optimal effect following intramuscular injection 
it is important that the drug be delivered to the muscle. 
Problems can arise if drugs designed to be absorbed from 
muscle are delivered into subcutaneous tissue. Increasing 
obesity in developed and many developing countries makes 
this an important concern.7 Other injection sites, such as the 
deltoid, have been suggested and could be more suitable for 
these patients. The currently available 3 mL formulation of 
injectable diclofenac precludes intradeltoid injection due to 
its larger injection volume.
A new propylene glycol-free and reduced-volume injec-
tion of diclofenac sodium has been developed. By using a 
combination of three classes of solvents containing mono-
hydric and polyhydric alcohols and a polyhydric alcohol 
ether in combination with water as the principal solvent, it 
has become possible to dissolve 75 mg of diclofenac in just 
1 mL of injection solution without a substantial increase 
in viscosity. This new formulation, when administered via 
the deltoid muscle, was observed to have a bioavailability 
comparable with the intragluteal formulation of diclofenac 
sodium 75 mg/3 mL in healthy adult Indian subjects.8
The bioavailability of this new formulation has not been 
defined in obese subjects. The World Health Organization has 
revised the body mass index (BMI) cutoff for Asian Indians, 
and suggested a BMI of 25 kg/m2 to define obesity rather 
than the 30 kg/m2 recommended for Europeans.9
The objective of the present study was to determine the 
pharmacokinetics of the new reduced-volume intradeltoid 
formulation of diclofenac sodium 75 mg/mL injection and 
to compare its bioavailability with that of the intragluteal 
75 mg/3 mL formulation in adult male Indian subjects with 
a BMI . 25.
Material and methods
The study was carried out in 10 volunteers with a BMI . 25 
at the B.V. Patel Pharmaceutical Education and Research 
Development Centre, Ahmedabad, India. All subjects pro-
vided written informed consent to participate in the study 
prior to enrolment, and were free to withdraw at any time 
during the study. The study was approved by the Institutional 
Ethics Committee and was conducted in accordance with 
Good Clinical Practice and the Declaration of Helsinki.
Subjects
The study population consisted of 10 adult male subjects with 
a BMI . 25 (mean 26.85, range 25.30–31.16), of mean age 
32.3 (25–39) years, mean weight 76.5 (68–89) kg, and mean 
height 168.7 (163–173) cm.
Design
This study was an open-label, randomized, single-dose, 
two-way, crossover, comparative bioavailability study that 
assessed the two injectable formulations of diclofenac under 
fasting conditions, during two separate dosing periods, with 
a washout period of seven days between the two periods. The 
volunteers were administered each of the two study drugs 
after an overnight fast. Dose administration was performed 
as per the randomization schedule generated at the B.V. Patel 
Pharmaceutical Education and Research Development Cen-
tre, Ahmedabad, India. Subjects received single doses of the 
intradeltoid test formulation (diclofenac 75 mg/mL, Troikaa 
Pharmaceuticals Ltd., India) and the intragluteal reference for-
mulation (Voveran®, diclofenac 75 mg/3 mL, Novartis, India). 
Intramuscular injections were administered using BD Preci-
sionGlide needles (Becton Dickinson India Pvt. Ltd., India, 
23 G 0.6 × 25 mm) and BD 2 mL Discardit II™ syringes.
Blood sampling
Following administration of the test/reference formulation in 
each period, a total of 16 blood samples of 6 mL each were 
collected before dosing and at 10, 20, 30, 40, and 50 minutes, 
and 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, and 6.0 hours 
following drug administration. During each session, an 
indwelling catheter was inserted into a forearm vein. Samples 
were collected in tubes containing lithium heparinate and 
immediately centrifuged at 4°C. Plasma was separated and 
frozen at −70°C until further analysis.
Method of analysis
After the addition of 0.05 mL internal standard (mefenamic 
acid) 25 µg/mL, 0.5 mL plasma samples were acidified with 
0.05 mL 6% trichloroacetic acid. The drug was extracted 
into dichloromethane 5 mL. The dichloromethane layer 
was separated and evaporated under nitrogen gas, and then 
reconstituted in a 0.1 mL mobile phase. A 0.06 mL solution 
was injected into the column of a high-pressure liquid chro-
matography system (Jasco 900 series, Japan) equipped with 
a PU 980 pump, AS 950 autosampler, and UV 975 detec-
tor. Separations were achieved using a Grace Vydac 5 µm 
ODS (4.6 × 250 mm) column (Separations Group Inc, W.R. 
Grace & Co., Columbia, MD, USA) with a mobile phase 
consisting of acetonitrile and 0.01 M, pH 6.6 potassium 
dihydrogen orthophosphate buffer (40:60, % v/v) at a flow 
rate of 0.8 mL/min under ultraviolet detection at 282 nm. 
The samples were analyzed at 30°C with a linear range of 
0.1–6 µg/mL (y = 0.3572x + 0.0019; r = 0.999), with an 
average recovery of 68%. The intraday and between-day Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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coefficients of variation (%CV) of all the quality control 
samples were ,5% and ,4%, respectively. The accuracy of 
the method was between 90% and 110%. The lowest value on 
the calibration curve was the lower limit of quantitation, ie, 
0.1 µg/mL, and the limit of detection was 0.025 µg/mL.
Pharmacokinetic analysis
The pharmacokinetic parameters measured include the 
observed maximum plasma concentration (Cmax), time to 
reach Cmax (Tmax), and the area under the plasma concentra-
tion-time curve from 0 hours to the time point of last measur-
able concentration (AUC0–t) and 0 hours to infinity (AUC0–∞). 
The Cmax and Tmax were directly determined from the plasma 
concentration versus time curves. The AUC0–t from time zero 
to the last quantifiable point (Ct) was calculated using the 
trapezoidal rule, and the extrapolated AUC from Ct to infinity 
(AUC0–∞) was determined as Ct/kl. AUC0–∞ was calculated as 
the sum of the AUC0–t plus the ratio of the last measurable 
concentration to the elimination rate constant (k). Logarith-
mic transformation was done before data analysis for Cmax, 
AUC0–t, and AUC0–∞. Analysis of variance (ANOVA) was 
used to assess effects. Intrasubject variability in terms of the 
overall %CV was evaluated from the ANOVA results for Ln-
transformed data. For the pharmacokinetic parameters Cmax, 
AUC0–t, and AUC0–∞, 90% confidence intervals (CI) for the 
ratios of test and reference product averages were calculated 
using ANOVA of the Ln-transformed data. Consistent with 
the two one-sided tests for bioequivalence, 90% CIs for the 
ratio of both the product averages were calculated by first 
calculating the 90% CI for the differences in the averages of 
the Ln-transformed data and then taking the antilogarithms 
of the CI obtained.
Safety and tolerability
General clinical safety was assessed via physical examination 
and vital signs at screening and at the end of the study. Clinical 
laboratory tests and electrocardiograms were also conducted 
at screening, before dosing within each treatment period, 
and at the end of the study. Adverse events were assessed for 
severity and relationship to treatment throughout the study.
Results
Analytic method
A reverse-phase high-pressure liquid chromatographic 
method was developed to determine the bioavailability of 
diclofenac after administration of the two formulations. 
The calibration range was selected based on expected body 
concentrations. The method was specific and selective 
for the analyte, and good linearity was observed within 
the range. Sufficient recovery was obtained by extraction 
under acidic conditions in dichloromethane. The preci-
sion and accuracy of the method made it suitable for the 
intended use.
Pharmacokinetic parameters
The mean plasma concentration-time profiles of diclofenac 
sodium following administration of single doses to 10 obese 
volunteers are shown in Figure 1, and a summary of the phar-
macokinetic parameters is presented in Table 1. Mean Cmax 
and mean Tmax for the test formulation were 1.30 ± 0.18 µg/
mL and 0.50 ± 0.16 hours, respectively, and 0.93 ± 0.14 µg/
mL and 1.08 ± 0.31 hours for the reference formulation. Peak 
plasma concentrations reported in the literature have ranged 
from 1.89 to 2.15 µg/mL following an intramuscular injec-
tion of diclofenac 75 mg.8,10 Variable values of Tmax have been 
reported, ranging from 3.1 to 6.4 hours for diclofenac sodium 
with different formulations in healthy subjects.11
The mean AUC0–t for the test and reference formulations 
was 2.71 ± 0.39 µg⋅h/mL and 2.73 ± 0.49 µg⋅h/mL, respec-
tively. The mean AUC0–∞ for the test and reference formu-
lations was 3.71 ± 0.52 µg⋅h/mL and 3.75 ± 0.58 µg⋅h/mL, 
respectively. AUC0–t and AUC0–∞ values are in line with those 
we have reported earlier for healthy volunteers.8
The mean elimination rate constant kel and mean t1/2 for 
the test and reference formulations were 0.11 ± 0.02 h−1 and 
6.30 ± 1.27 hours, and 0.12 ± 0.02 h−1 and 5.93 ± 1.11 hours 
respectively. The point estimate, 90% and 95% CI, and 
summary of statistics are tabulated in Tables 2 and 3, 
respectively.
The statistical analysis revealed no significant differ-
ences between the test and reference formulations for Cmax, 
AUC0–t, and AUC0–∞, suggesting that the pharmacokinetic 
profile is similar between the two formulations. The %CV 
corresponding to intrasubject variability was 9.18%, 5.92%, 
and 7.95% for Cmax, AUC0–t, and AUC0–∞, respectively. The 
means (90% CI) of the Cmax, AUC0–t, and AUC0–∞ for the 
test:reference ratios were 1.39 (129.8, 151.3), 0.993 (94.6, 
104.4), and 0.989 (92.9, 106.08), respectively.
Safety and tolerability
All 10 subjects completed the study, during which there were 
no premature withdrawals or deaths. No serious adverse 
events were recorded, and there were no clinically significant 
changes in vital signs, clinical laboratory variables, electro-
cardiographic parameters, or physical examination findings 
during the study.Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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Figure 1 Linear plot of mean plasma concentrations (µg/mL) versus time profile of diclofenac sodium for test and reference formulations in 10 obese (BMI . 25) male 
subjects under fasting conditions. 
Abbreviations: SeM, standard error of mean; BMi, body mass index.
Table 1   Mean  pharmacokinetic  parameters  in  10  obese  male  volunteers  following  intragluteal  administration  of  the  reference 
formulation (diclofenac sodium 75 mg/3 mL) and test formulation (diclofenac sodium 75 mg/1 mL)
Formulation A (reference) Formulation B (test)
Cmax
(μg/mL)
Tmax
(h)
AUC0–t
(μg . h/mL)
AUC0–∞
(μg . h/mL)
t1/2
(h)
kel
(h−1)
Cmax
(μg/mL)
Tmax
(h)
AUC0–t
(μg . h/mL)
AUC0–∞
(μg . h/mL)
t1/2
(h)
kel
(h-1)
Mean 0.93 1.08 2.73 3.75 5.93 0.12 1.30 0.50 2.71 3.71 6.30 0.11
SD 0.14 0.31 0.49 0.58 1.11 0.02 0.18 0.16 0.39 0.52 1.27 0.02
%cV 15.53 28.34 17.80 15.53 18.64 17.83 14.18 31.65 14.53 14.02 20.11 20.97
Abbreviations: cmax, maximum measured plasma concentration; Tmax, time of maximum measured plasma concentration; AUc0–t, area under the plasma concentration 
versus time curve from time zero to the last measurable concentration; AUc0–∞, area under the plasma concentration versus time curve from zero to infinity; t1/2, time 
required for the plasma drug concentration to decrease by one-half; kel, apparent first order elimination or terminal rate constant; SD, standard deviation; %CV, coefficient 
of variation.
Discussion
Depending on the depth of fat, intramuscular injections using 
standard 35 mm and 25 mm needles may be injected subcu-
taneously in a significant number of patients, and not into the 
gluteal musculature. This could alter the pharmacokinetics of 
the administered medication. Hence, an alternative injection 
site should probably be chosen to increase the success rate of 
intramuscular deposition of medication.7 The deltoid muscle 
has been suggested as an alternative site for intramuscular 
drug administration. Several reports have suggested that this 
is a better site for injection than the gluteal musculature.12,13
Based on deltoid fat pad thickness determination, it 
has been observed that for men weighing 59–118 kg, use 
of a 25 mm needle would result in at least 5 mm of muscle 
penetration in all subjects. For women weighing less than 
60 kg, a 16 mm needle would be sufficient to achieve muscle 
penetration of 5 mm. For women weighing 60–90 kg, a 
25 mm needle would be sufficient, and women weighing 
more than 90 kg would require a 38 mm needle to enable 
intramuscular administration.14 Similar observations were 
reported by Cook et al,15 who suggested that in all males 
and females with a BMI , 35, intramuscular injection into 
the deltoid could be achieved with a 25 mm needle, whilst 
in females with a BMI . 35, a 35 mm needle is required. 
Thus, standard needles would reach the muscle in patients 
by intradeltoid administration.
To address the need for an intradeltoid route to 
inject diclofenac sodium, a new formulation containing 
75 mg/mL was developed. We have previously reported that 
the new formulation of injectable intradeltoid diclofenac Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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75 mg/mL is bioequivalent to the intragluteal diclofenac 
sodium 75 mg/3 mL reference formulation.8
All 10 subjects completed the study and were included 
for both statistical and analytic analysis. Based on repeated-
measures ANOVA, subject, period, treatment, and interaction 
term (period × treatment) showed a nonsignificant difference. 
The P values suggest that there is no statistically significant 
difference. The 90% CIs for all the pharmacokinetic parameters 
were within bioequivalence acceptance criteria, with the only 
exception being Cmax, for which the upper bound was above 
the 125% limit.
With regard to the extent of absorption, the AUC0–t and 
AUC0–∞ were comparable between the test and reference 
formulations. Mean Cmax was higher for the test formula-
tion, but this difference was not statistically significant. Tmax 
was earlier for the test formulation than for the reference 
  formulation (0.50 hours versus 1.08 hours, respectively). 
Earlier Tmax and slightly higher Cmax may be attributed to the 
depth of subcutaneous fat in the gluteal region and better 
blood flow to the deltoid than to the gluteus muscle.16
Diclofenac has been reported to be associated with 
gastrointestinal, cardiovascular, and hepatic side effects.17 
The most common side effects following diclofenac injec-
tion are gastrointestinal and pain at site of injection.18 
Mild to moderate adverse events have been reported in 
about 5% patients with renal colic following intramuscu-
lar diclofenac.19 Only minor gastrointestinal side effects 
have been reported following intramuscular diclofenac 
postoperatively.20 In the present study, both formula-
tions were well tolerated, and no adverse events were 
reported.
Conclusion
Our results suggest that the test formulation of diclofenac 
sodium 75 mg/mL has a comparable AUC0–t and AUC0–∞ 
but an earlier Tmax and a trend towards a higher Cmax in com-
parison with the reference diclofenac sodium 75 mg/3 mL 
formulation. This could be attributed to faster absorption 
from the deltoid region than from the gluteal region. The 
test formulation, which can be given by the intradeltoid 
route using standard needles, would be helpful in the man-
agement of postoperative pain and other painful conditions. 
This formulation would be especially useful in obese or 
overweight patients and those with dense subcutaneous fat 
in the gluteal region, in whom intramuscular injections into 
the gluteus musculature using standard needles may fail to 
reach the muscle.
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Table 3 Summary statistics of diclofenac sodium in 10 obese 
adult subjects under fasting conditions
Parameters 
summary  
statistics
Product Cmax AUC0–t AUC0–∞
(μg/mL) (μg . h/mL) (μg . h/mL)
geometric mean Test 
Reference
1.29 
0.92
2.68 
2.69
3.68 
3.71
LSM Test 
Reference
1.29 
0.92
2.68 
2.69
3.68 
3.71
LSM ratio B/A % 140.22 99.6 99.19
90% confidence interval: B/A
  Lower limit 129.8 94.6 92.9
  Upper limit 151.13 104.4 106.08
P value (AnOVA)
  Period .0.05 .0.05 .0.05
  Formulation .0.05 .0.05 .0.05
  Sequence .0.05 .0.05 .0.05
intrasubject variability: %cV  9.18 5.92 7.95
Abbreviations:   c max,  maximum  measured  plasma  concentration;  AUc0–t,  area 
under  the  plasma  concentration  versus  time  curve  from  time  zero  to  the  last 
measurable concentration; AUc0–∞, area under the plasma concentration verses 
time curve from zero to infinity; LSM, least squares mean; A, reference product; 
B, test product; AnOVA, analysis of variance; B/A, bioavailability ratio test (B)/
Reference (A); %CV, coefficient of variation.
Table 2 Point estimate, 90% and 95% confidence intervals for the ratio of the product averages of test and reference formulations
Parameter Point 
estimate test: 
Reference
90% confidence interval 95% confidence interval P value
Lower confidence 
limit
Upper confidence 
limit
Lower confidence 
limit
Upper confidence 
limit
cmax 1.39 129.8 151.3 127.4 153.7 0.946
AUc0–t 0.993 94.6 104.4 93.5 105.7 0.135
AUc0–∞ 0.989 92.9 106.08 91.5 107.8 0.193
Abbreviations: cmax, maximum measured plasma concentration; AUc0–t, area under the plasma concentration versus time curve from time zero to the last measurable 
concentration; AUc0–∞, area under the plasma concentration versus time curve from zero to infinityJournal of Pain Research
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